Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

CSIR-IICT ties up with Cipla to develop anti-COVID-19 drug

Mar 17, 2020, 22:46 IST

PTI

Hyderabad, Mar 17 (): Hyderabad-based CSIR-IndianInstitute of Chemical Technology (IICT) has tied up withpharmaceutical giant Cipla to work on development of anti-viral drugs to contain COVID-19.

Research on anti-viral drugs has been on throughout theworld for long and many companies have developed moleculeshaving anti-viral properties. But due to lack of demand, thesemolecules were not widely marketed, according to IICT sources.

However, the CSIR-IICT decided to work on three suchmolecules -- remdesivir, favipiravir and baloxavir. Ciplaurged the IICT director S Chandrasekhar to start work on thesemolecules on an immediate basis.

Quoting a top official of Cipla, the sources said Ciplawould upscale the process on the basis of know-how given byCSIR-IICT. SJR VVKNVG NVG

(This story has not been edited by www.businessinsider.in and is auto–generated from a syndicated feed we subscribe to.)